NorthSea Therapeutics Strengthens Leadership with New CFO and CMO
Portfolio - People | Feb 20, 2025 | Ysios Capital
NorthSea Therapeutics B.V., a late-stage clinical biotechnology company, has announced the addition of two key personnel to its leadership team. Melissa Bradford-Klug joins as Chief Financial Officer and Chief Business Officer, with a proven track record in strategic finance and business development in the rare disease sector. Dr. Sophie Jeannin is appointed as Chief Medical Officer, bringing her expertise in research, clinical development, and regulatory strategy for metabolic and orphan diseases. The company's pipeline includes innovative therapies for metabolic, cholestatic, and fibrotic diseases, with several clinical trials underway. NorthSea has secured significant financial backing, including an $80 million Series C funding round co-led by Ysios Capital and Forbion Growth. The new appointments aim to enhance the company's growth prospects as it advances its mission of delivering transformative treatments to patients.
Sectors
- Biotechnology
- Pharmaceuticals
Geography
- Netherlands – NorthSea Therapeutics is headquartered in the Netherlands, indicating its primary geographical location.
- United States – The company also has a presence in the U.S., highlighting its international operations and market focus.
- Norway – NorthSea Therapeutics has activities in Norway, indicating its geographical spread in Europe.
Industry
- Biotechnology – The article centers around NorthSea Therapeutics, a biotechnology company developing therapies for metabolic, cholestatic, and fibrotic diseases.
- Pharmaceuticals – Key appointments involve experts with experience in pharmaceuticals and drug development, significant in NorthSea’s focus on novel therapeutic approaches.
Financials
- $80M – Series C financing round co-led by Ysios Capital and Forbion Growth.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| NorthSea Therapeutics B.V. | Target Company | Company | A private, late-stage clinical biotechnology company developing therapies for metabolic, cholestatic, and fibrotic diseases. |
| Ysios Capital | Investor | PE Firm | Co-leader of NorthSea’s $80M Series C financing. |
| Melissa Bradford-Klug | Chief Financial Officer and Chief Business Officer | Person | Newly appointed executive with extensive experience in corporate strategy, strategic finance, and business development in the rare disease space. |
| Sophie Jeannin | Chief Medical Officer | Person | Experienced executive in research, clinical development, and regulatory strategy for metabolic and orphan diseases. |
| Forbion Growth | Investor | Company | Co-leader of NorthSea’s $80M Series C financing. |
| venBio, Novo Seeds, Sofinnova, BGV, New Science Ventures | Investors | Company | Supporters of NorthSea’s $80M Series C financing. |